Mangalam Drugs and Organics Ltd

Mangalam Drugs and Organics Ltd

₹ 102 -0.07%
24 Apr 3:28 p.m.
About

Incorporated in 1977, Mangalam Drugs
& Organics Ltd manufactures Active Pharmaceutical Ingredients and
Intermediates[1]

Key Points

Business Overview:[1]
Company manufactures bulk drugs, organic and inorganic chemicals. It is among the few companies which are World Health Organization -approved Indian companies to be associated with the William J Clinton Foundation for manufacture of anti-malarial drugs. Company supplies artemisinin-based bulk drugs to pharmaceutical companies, for manufacturing anti-malarial formulations

  • Market Cap 161 Cr.
  • Current Price 102
  • High / Low 132 / 85.2
  • Stock P/E
  • Book Value 87.8
  • Dividend Yield 0.00 %
  • ROCE 6.25 %
  • ROE 0.84 %
  • Face Value 10.0

Pros

  • Stock is trading at 1.17 times its book value

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 6.71% over past five years.
  • Company has a low return on equity of 11.9% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
88.69 92.90 104.78 123.02 101.88 120.96 109.49 108.33 63.32 91.11 87.46 81.56 97.34
76.09 81.32 94.43 109.26 87.56 110.77 99.12 99.89 56.84 90.87 90.94 79.37 90.36
Operating Profit 12.60 11.58 10.35 13.76 14.32 10.19 10.37 8.44 6.48 0.24 -3.48 2.19 6.98
OPM % 14.21% 12.47% 9.88% 11.19% 14.06% 8.42% 9.47% 7.79% 10.23% 0.26% -3.98% 2.69% 7.17%
1.27 0.00 0.52 0.00 0.00 0.00 0.01 0.00 0.13 0.29 0.02 0.03 0.00
Interest 2.35 2.22 2.96 2.98 2.69 2.53 3.54 2.56 3.22 3.43 3.41 3.24 3.31
Depreciation 2.33 2.52 2.39 2.50 2.67 2.69 2.60 2.76 2.88 2.75 3.42 3.73 3.62
Profit before tax 9.19 6.84 5.52 8.28 8.96 4.97 4.24 3.12 0.51 -5.65 -10.29 -4.75 0.05
Tax % 30.03% 68.57% 19.93% 45.41% 55.02% -34.61% 29.01% 28.85% 15.69% 22.30% 7.29% 25.05% -920.00%
6.43 2.15 4.42 4.53 4.02 6.69 3.00 2.23 0.43 -4.39 -9.54 -3.56 0.50
EPS in Rs 4.06 1.36 2.79 2.86 2.54 4.23 1.90 1.41 0.27 -2.77 -6.03 -2.25 0.32
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
153 124 123 221 295 299 269 228 282 380 451 372 357
139 129 113 200 257 252 222 218 259 327 402 347 352
Operating Profit 14 -4 10 20 38 47 47 10 24 53 49 26 6
OPM % 9% -4% 8% 9% 13% 16% 17% 4% 8% 14% 11% 7% 2%
1 2 0 0 0 -0 1 0 1 5 0 0 0
Interest 10 10 10 10 9 10 12 9 10 9 11 13 13
Depreciation 4 4 4 4 4 5 7 7 8 9 10 11 14
Profit before tax 1 -17 -4 6 24 31 29 -6 6 40 28 2 -21
Tax % 44% 30% 22% -2% 33% 29% 32% -40% -32% 29% 29% 43%
1 -12 -3 6 16 22 20 -8 8 28 20 1 -17
EPS in Rs 0.48 -8.95 -2.31 4.66 11.15 14.08 12.57 -5.07 5.21 17.67 12.42 0.80 -10.73
Dividend Payout % 0% 0% 0% 0% 0% 0% 4% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 12%
5 Years: 7%
3 Years: 10%
TTM: -11%
Compounded Profit Growth
10 Years: 8%
5 Years: -42%
3 Years: -46%
TTM: -238%
Stock Price CAGR
10 Years: 36%
5 Years: 13%
3 Years: -7%
1 Year: -10%
Return on Equity
10 Years: 13%
5 Years: 8%
3 Years: 12%
Last Year: 1%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 13 13 13 13 14 16 16 16 16 16 16 16 16
Reserves 25 13 10 16 39 70 88 80 88 115 135 136 123
61 73 77 78 60 66 69 65 52 70 88 89 89
23 16 25 63 47 38 54 50 75 64 90 119 159
Total Liabilities 122 115 125 170 160 190 227 211 231 264 328 360 387
57 55 53 53 54 93 102 103 101 118 135 142 151
CWIP 0 0 0 0 5 0 0 0 1 6 6 9 0
Investments 0 0 0 0 0 2 0 0 0 0 0 0 0
65 59 72 117 100 95 125 107 128 140 188 208 236
Total Assets 122 115 125 170 160 190 227 211 231 264 328 360 387

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
7 -1 7 14 22 43 25 22 31 28 26 40
-6 -2 -2 -4 -11 -39 -16 -9 -7 -31 -27 -22
-0 2 -5 -10 -11 -3 -9 -11 -23 3 3 -17
Net Cash Flow 0 -1 0 1 -0 0 -0 1 0 -1 1 1

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 21 70 88 73 37 45 61 28 52 52 38 46
Inventory Days 165 112 170 134 85 69 132 175 121 85 139 200
Days Payable 43 39 97 128 37 38 82 77 106 63 65 141
Cash Conversion Cycle 143 144 161 79 85 75 111 126 67 74 112 104
Working Capital Days 96 125 122 79 76 70 99 102 66 75 84 93
ROCE % 12% -7% 6% 16% 30% 32% 25% 2% 11% 27% 18% 6%

Shareholding Pattern

Numbers in percentages

6 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
50.53% 50.53% 50.53% 50.53% 50.42% 50.41% 50.31% 50.31% 50.31% 50.31% 50.31% 50.31%
0.00% 0.00% 0.00% 0.10% 0.10% 0.10% 0.10% 0.10% 0.10% 0.10% 0.10% 0.26%
0.01% 0.01% 0.01% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
49.46% 49.46% 49.46% 49.36% 49.47% 49.49% 49.58% 49.59% 49.58% 49.59% 49.59% 49.42%
No. of Shareholders 21,82721,07120,66820,08418,98818,48317,91117,94317,89017,97818,61019,173

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents